Alzheimer’s Disease (AD) is one of the biggest challenges in our aging society. Despite huge efforts, the FDA only approved the first disease modifying agent ever at the beginning of this year.
The conference in Gothenburg was an excellent opportunity to take the pulse of the Alzheimer’s community. Here are our key learnings:
We attended the ASCO 2023 annual meeting in Chicago. After the rise of immuno-oncology, COVID-19 challenged clinical trial execution and muted patient numbers. In the last years we saw many setbacks of once promising immuno-oncology combinations trials.
What mattered this month in healthcare? Q1 reporting came to a close, and FTC action put pressure on the biopharma space and... Find out more in our monthly healthcare newsletter.
With M&A picking up, are we at a turning point for biotech? Check out our latest Kieger AG Chart of the Month Video.